Gilteritinib vs salvage chemotherapy in FLT3-mutated acute myeloid leukemia: number needed to treat for clinical outcomes per a secondary analysis of the ADMIRAL trial.

Approximately 30% of patients newly diagnosed with acute myeloid leukemia (AML) have FMS-like tyrosine kinase 3 mutations (FLT3mut+), conferring a negative effect on prognosis with a high likelihoo...